KPV Tripeptide: Anti-Inflammatory and Gut Health Research Guide

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from the C-terminus of α-MSH (alpha-melanocyte-stimulating hormone). The full α-MSH sequence (13 amino acids) terminates with the sequence Lys-Pro-Val-NH₂. Research has demonstrated that this C-terminal tripeptide retains significant biological activity — particularly anti-inflammatory properties — in multiple in vitro and in vivo model systems.

KPV's small size (molecular weight ~356 Da) gives it properties distinct from larger peptides: it may be more stable to enzymatic degradation, can potentially penetrate mucosal barriers, and is relatively straightforward to synthesise to high purity.

KPV exerts anti-inflammatory effects through several identified mechanisms:

• NF-κB inhibition — KPV reduces nuclear translocation of NF-κB p65 subunit in macrophages and intestinal epithelial cells, attenuating transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6
• Melanocortin receptor signalling — as an α-MSH fragment, KPV retains partial activity at MC1R and MC3R, which mediate anti-inflammatory cAMP signalling in immune cells
• Direct intracellular activity — some studies suggest KPV can act intracellularly within macrophages to modulate inflammatory signalling independently of surface receptor binding, possibly due to its small size enabling intracellular accumulation

The most extensively studied application of KPV is intestinal inflammation. Studies in rodent colitis models (DSS-induced and TNBS-induced) have demonstrated that KPV administration reduces colonic inflammation markers including:

• Histological inflammation scores (mucosal damage, immune cell infiltration)
• Colonic cytokine levels (IL-1β, TNF-α, IL-6)
• Myeloperoxidase (MPO) activity — a marker of neutrophil infiltration

KPV has been investigated both as a systemically administered agent and in targeted delivery formulations designed to concentrate the peptide at the intestinal mucosa. Its stability to luminal degradation (compared to longer peptides) makes it a candidate for oral delivery research in gut inflammation models.

α-MSH has well-documented roles in skin biology, and KPV has been examined in wound healing contexts as its active fragment. Studies in skin wound models have shown KPV can reduce local inflammation and promote healing, consistent with its NF-κB inhibitory mechanism. Its effect on keratinocyte migration and proliferation is a subject of ongoing preclinical investigation.

For researchers investigating multi-pathway tissue repair, KPV is also available as a component of the KLOW 80mg blend — combining KPV (10mg) with GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg) in a single lyophilised vial. This combination allows investigation of synergistic anti-inflammatory and regenerative mechanisms without requiring separate reconstitution of each component.

RetaLABS KPV 10mg is supplied as lyophilised powder. Reconstitute with bacteriostatic water or sterile saline; store lyophilised at −20°C and reconstituted at 2–8°C for up to 4 weeks. See the Peptide Reconstitution Guide for full protocol notes. COAs available on request. For laboratory research use only.